NTRK
8 drugsNeurotrophic Tyrosine Receptor Kinase
Predictive biomarker for patient selection in 14 indications
Understanding NTRK
What it means: NTRK gene fusions (NTRK1, NTRK2, NTRK3) create oncogenic fusion proteins. Found across many cancer types at low frequency.
Why it matters: NTRK inhibitors larotrectinib and entrectinib show >75% response rates regardless of tumor type (tumor-agnostic approval).
Testing: Tested via NGS (preferred), FISH, or IHC (pan-TRK screening). NGS captures all fusion partners.
8
Approved Drugs
14
Indications
7
Companies
NTRK is a precision-medicine biomarker linked to 8 FDA-approved targeted drugs from 7 companies, spanning 14 indications including Solid tumors with a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, Metastatic solid tumors with NTRK gene fusion, Solid tumors with NTRK gene fusion where surgical resection is likely to result in severe morbidity. Explore the targeted therapies, indications, testing methods, and companies developing NTRK drugs below.
Search NTRK Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting NTRK
NTRK Indications
Solid tumors with a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation Metastatic solid tumors with NTRK gene fusion Solid tumors with NTRK gene fusion where surgical resection is likely to result in severe morbidity Solid tumors with NTRK gene fusion that have progressed following treatment or have no satisfactory alternative treatments ROS1-positive metastatic non-small cell lung cancer (NSCLC) in adults NTRK gene fusion-positive solid tumors in adult and pediatric patients older than 1 month Non-Small Cell Lung Cancer Metastatic RET fusion-positive non-small cell lung cancer Advanced or metastatic RET fusion-positive thyroid cancer Solid Tumors Neurotrophic Keratitis Metastatic colorectal cancer Locally advanced, unresectable or metastatic gastrointestinal stromal tumor Hepatocellular carcinoma